127243-85-0
127243-85-0 结构式
基本信息
N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺
H-89 DIHYDROCHLORIDE
H-89 HYDROCHLORIDE
N-[2-(P-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE
N-[2-(P-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE 2HCL
N-[2-(P-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE, DIHYDROCHLORIDE
N-(2-[P-BROMOCINNAMYLAMINO]ETHYL)-5-ISOQUINOLINESULFONAMIDE HYDROCHLORIDE
N-[2-[P-BROMOCINNAMYLAMINO]-ETHYL]-5-ISOQUINOLINESULFONMIDE
物理化学性质
常见问题列表
IC50: 48 nM (protein kinase A)
H-89 inhibits protein kinase A, in competitive fashion against ATP. H-89 causes a dose-dependent inhibition of the forskolin-induced protein phosphorylation, with no decrease in intracellular cyclic AMP levels in PC12D cells. H-89 significantly inhibits the forskolin-induced neurite outgrowth from PC12D cells. H-89 (30 μM) inhibits significantly cAMP-dependent histone IIb phosphorylation activity in PC12D cell lysates. H-89 (1-2 μM) significantly slows the repriming rate in rat skinned fibres, most likely due to it deleteriously affecting the T-system potential. H-89 (10-100 μM) inhibits net Ca 2+ uptake by the SR and affectes the Ca 32 -sensitivity of the contractile apparatus in rat skinned fibres.
H-89 (0.2 mg/100g, i.p.) significantly increases seizure latency and threshold in PTZ-treated animals. H-89 (0.05, 0.2 mg/100 g, i.p.) prevents the epileptogenic activity of bucladesine (300 nM) with significant increase of seizure latency and seizure threshold.